Current trends in pharmaceutical and how they will affect you as a statistician

Interview with Richard Zink

What bigger trends do we see in the biopharmaceutical industry, which will have an impact for statisticians?
. . . in terms of technology changes?
. . . in terms of regulatory changes?
. . . in terms of political/society changes?
What can statisticians do to prepare for these changes?

In this discussion with the current ASA biopharm chair – Richard Zink – we’re covering a wide range of topics:

• Probabilistic matching
• Propensity scoring
• RWE before and after approval
• Understanding populations outside of RCTs
• Understanding background treatments and rates of adverse events
• Augmenting RCTs with RWE
• Data from different data sources
• Data from Devices and wearables
• Natural language processing and unstructured way
• Pragmatic trials
• AI and machine learning
• Data science
• Business analytics
• Prices of products
• Cost-effectiveness and budget impact models
• Umbrella studies

Richard Zink, PhD

Senior Director of Data Management and Statistics, TARGET PharmaSolutions

He is the 2019 Chair of the Biopharmaceutical Section of the American Statistical Association, host of the Biopharmaceutical Section Statistics Podcast, and Associate Editor for the DIA journal Therapeutic Innovation & Regulatory Science. Richard is author, editor, and contributor to 8 books on statistical topics in clinical trials and clinical research. He holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, where he serves as Adjunct Assistant Professor of Biostatistics.

Listen to this episode and learn to be an effective statistician!